Join Dr. Mariah Pierce, Technical Account Manager at Sino Biological, as she introduces Sino Biological's cutting-edge, high-throughput, cell-free expression platform. This platform facilitates the quick and economical screening of VHH and scFv antibodies in a matter of hours instead of weeks.
With the advent of advanced technologies generating increasingly large antibody sequence libraries, there is a growing need for high throughput (HTP) antibody expression and screening. These libraries are generated through conventional antibody development campaigns or AI and/or computational technologies.
Traditionally, antibody expression is completed in mammalian cell expression systems, which is often both time-intensive and costly. To address these challenges, Sino Biological has developed a cell-free expression platform that improves timelines, enhances expression outcomes for challenging targets, and reduces costs.
Utilizing E.coli cell lysates, the platform facilitates protein expression in small reactions for about 3-5 hours instead of days to weeks. The system has been optimized for small antibody fragments, including VHH (nanobody), scFvs (single-chain variable regions), and small peptides up to 200 amino acids for small scale screening at high capacity of 100+ sequences.
The platform is capable of achieving high levels of purity, yield, and affinity comparable to those typically observed in mammalian cell production.
Additionally, the small protein expression effectively bridges the gap between solid state synthesis and conventional recombinant expression 15kDa+.
Employing cell-free expression systems for high-throughput antibody library and small protein mutant library screening serves as a strategic method for mitigating the extended timelines linked to conventional mammalian systems.
Key objectives
- Describe cell-free protein expression.
- Explain the advantages of cell-free expression for antibodies.
- Discuss the capacity and quality of Sino Biological’s cell-free expression platform.
Keynote speaker
Dr. Mariah Pierce, Technical Account Manager at Sino Biological US, Inc.
Dr. Mariah Pierce is a Technical Account Manager at Sino Biological, specializing in managing custom projects. She has extensive experience in recombinant technology, encompassing bacterial, viral, insect, and mammalian protein expression as well as subsequent purifications and characterization.
With a unique background viewing biological challenges with a chemist’s point of view, Dr. Pierce earned her B.S. in Chemistry from the State University of New York at Potsdam and her Ph.D. in Chemistry from Syracuse University, where she worked to develop an expression protocol for a transmembrane bound active enzyme.